Gene-editing company Eligo Bioscience announce a successful $30 million Series B funding round, led by Sanofi Ventures.
The French company is focused on addressing diseases driven by the expression of bacterial genes from the microbiome.
By focusing on the in-vivo delivery of genetic cargoes to the microbiome, Eligo’s technology goes beyond traditional gene therapy and gene editing, expanding the range of addressable genetic targets.